# Prothea Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prothea-technologies

- Industry: Biotechnology
- Headquarters: Edinburgh, UK
- Website: www.prothea.tech/
- Total disclosed funding: $13M
- Latest round: Series A (Apr 1, 2024)
- Investors on record: 4

## About

Based in Scotland, Prothea Technologies Ltd. develops innovative medical solutions for lung cancer biopsy and treatment, streamlining patient procedures to improve outcomes and efficiency.Prothea Technologies Ltd. is focused on providing advanced medical solutions for lung cancer treatment. The company, headquartered in Edinburgh, UK, was founded by a group of medical professionals with extensive backgrounds in oncology. In April 2024, Prothea raised EUR 12 million in Series A funding, co-led by Earlybird Venture Capital and Merieux Equity Partners, among others. This funding targets a clinical trial for cancer imaging and biopsy procedures, marking a significant step in their strategic growth.Prothea Technologies specializes in innovative medical solutions aimed at improving the biopsy and treatment processes for lung cancer. Their offerings are designed to consolidate multiple procedures into a single hospital visit, effectively reducing treatment times from weeks to minutes. This innovation not only eases the burden on healthcare systems but also enhances patient outcomes. Prothea’s solutions cater to healthcare providers, hospitals, and clinics across North America and Europe, focusing on oncologists, radiologists, and healthcare administrators.Prothea Technologies generates revenue through business-to-business transactions with healthcare facilities that implement their lung cancer biopsy and treatment solutions. Clients engage in direct contracts for technology and services related to these procedures. The revenue model relies on long-term partnerships with hospitals, integrating Prothea’s innovative solutions into standard patient care, although specific pricing for offerings has not been publicly disclosed.Prothea Technologies plans to utilize the recent EUR 12 million raised in Series A funding to initiate clinical trials for cancer imaging, biopsy, and laser ablation treatments for lung cancer patients. The company aims to expand its market presence by targeting new regions in Europe and North America over the next two years. With this funding, Prothea intends to advance their product development and enhance their operational capabilities, positioning themselves for future growth in the oncology sector.

## Funding rounds

- Series A, Apr 1, 2024, $13M — Earlybird, NRW Bank, Merieux Equity Partners, Old College Capital

## Investors

- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series A
- NRW Bank — Series A
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series A
- Old College Capital (https://capitalatlas.ai/funds/old-college-capital) — Series A